Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vsv-indiana hiv gag
- Development stage
- Phase 1
- Lead developer
- Aurobindo Pharma
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VSV-Indiana HIV gag is a recombinant viral vector vaccine candidate developed by Profectus BioSciences in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). It utilizes a live-attenuated, replication-competent Vesicular Stomatitis Virus (VSV) Indiana serotype vector engineered to express the HIV-1 Gag protein. The Gag protein is a highly conserved internal structural protein of HIV, intended to elicit robust T-cell mediated immune responses. The vaccine has been evaluated in Phase 1 clinical trials both as a standalone agent in healthy volunteers and as a booster following DNA vaccine priming (such as the Profectus HIV MAG pDNA vaccine) in both HIV-uninfected and HIV-infected individuals. The goal of this approach is to induce long-lasting cellular immunity to control or prevent HIV infection.
- Brand names
- VesiculoVax HIV gag vaccine
- Other names
- rVSV-HIV-1 gagrVSV-HIV1 gagrVSV-HIV 1 gagrecombinant vesicular stomatitis virus HIV-1 gag vaccinerVSV-Indiana HIV-1 gag
02
Targets
Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on vsv-indiana hiv gag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vsv-indiana hiv gag.